William Grossman, M.D., Ph.D., Named to BryoLogyx Board of Directors

BryoLogyx Inc., ( www.BryoLogyx.com ), a privately-held, pre-clinical company developing a new class of proprietary drugs to enhance the response rates and treatment durability of cancer immunotherapies, announced today that the Company has named William Grossman, M.D., Ph.D., to its Board of Directors.